Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
---|
D001151 |
Arsenic |
Arsenic affects the expression of EPB41L3 mRNA | affects expression | 18414638
|
D019256 |
Cadmium Chloride |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromium oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of EPB41L3 mRNA | affects cotreatment|decreases expression | 12634122
|
C023600 |
chromium oxide |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromium oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of EPB41L3 mRNA | affects cotreatment|decreases expression | 12634122
|
C017133 |
chromous chloride |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromium oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of EPB41L3 mRNA | affects cotreatment|decreases expression | 12634122
|
C014347 |
decitabine |
decitabine affects the expression of EPB41L3 mRNA | affects expression | 17260099
|
D005047 |
Etoposide |
EPB41L3 protein affects the susceptibility to Etoposide | affects response to substance | 16217747
|
C008261 |
lead acetate |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromium oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of EPB41L3 mRNA | affects cotreatment|decreases expression | 12634122
|
D015735 |
Mifepristone |
Mifepristone results in increased expression of EPB41L3 mRNA | increases expression | 17584828
|
C017947 |
sodium arsenite |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromium oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of EPB41L3 mRNA | affects cotreatment|decreases expression | 12634122
|
D014284 |
Triiodothyronine |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of EPB41L3 mRNA | affects cotreatment|decreases expression | 14761676
|
D013749 |
Tetrachlorodibenzodioxin |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of EPB41L3 mRNA | affects cotreatment|decreases expression | 14761676
|
Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
---|
MESH:D000014 |
Abnormalities, Drug-Induced |
|
Tetrachlorodibenzodioxin |
3.04 | 15322242 11752688 14514962 |
MESH:D018248 |
Adenoma, Liver Cell |
|
Tetrachlorodibenzodioxin |
3.57 | 16835633 |
MESH:D000310 |
Adrenal Gland Neoplasms |
|
sodium arsenite |
4.92 | 15276417 |
MESH:D018246 |
Adrenocortical Adenoma |
|
Arsenic |
14.53 | 17306315 |
MESH:D018246 |
Adrenocortical Adenoma |
|
sodium arsenite |
14.53 | 17306315 16712894 |
MESH:D000740 |
Anemia |
|
Tetrachlorodibenzodioxin |
3.08 | 11748828 |
MESH:D020261 |
Arsenic Poisoning |
|
Arsenic |
2.90 | 16835338 18414634 12569548 16251483 |
MESH:D050197 |
Atherosclerosis |
|
Arsenic |
3.33 | 19371607 12928151 |
MESH:D001778 |
Blood Coagulation Disorders |
|
Tetrachlorodibenzodioxin |
3.18 | 12125929 |
MESH:D001836 |
Body Weight Changes |
|
Tetrachlorodibenzodioxin |
4.01 | 15340226 |
MESH:D001848 |
Bone Diseases, Developmental |
|
Tetrachlorodibenzodioxin |
2.85 | 15746008 |
MESH:D019046 |
Bone Marrow Neoplasms |
|
Etoposide |
5.38 | 14601052 |
MESH:D001943 |
Breast Neoplasms |
marker/mechanism |
|
| 17260099 |
MESH:D001943 |
Breast Neoplasms |
|
decitabine |
1.99 | 18320071 19208741 |
MESH:D001943 |
Breast Neoplasms |
|
Etoposide |
1.99 | 16322251 |
MESH:D001943 |
Breast Neoplasms |
|
Tetrachlorodibenzodioxin |
1.99 | 20435547 |
MESH:D002277 |
Carcinoma |
|
Tetrachlorodibenzodioxin |
2.91 | 16835633 |
MESH:D002280 |
Carcinoma, Basal Cell |
|
Arsenic |
3.66 | 15504454 17687452 |
MESH:D006528 |
Carcinoma, Hepatocellular |
|
Arsenic |
3.29 | 17306315 16507464 |
MESH:D006528 |
Carcinoma, Hepatocellular |
|
sodium arsenite |
3.29 | 17306315 16507464 15276417 |
MESH:D002294 |
Carcinoma, Squamous Cell |
|
Arsenic |
7.85 | 17687452 18922899 15504454 |
MESH:D002294 |
Carcinoma, Squamous Cell |
|
decitabine |
7.85 | 19215824 |
MESH:D002294 |
Carcinoma, Squamous Cell |
|
sodium arsenite |
7.85 | 18572023 |
MESH:D002295 |
Carcinoma, Transitional Cell |
|
Arsenic |
4.21 | 18640142 |
MESH:D006332 |
Cardiomegaly |
|
Tetrachlorodibenzodioxin |
2.44 | 18670907 18850075 16120746 |
MESH:D002318 |
Cardiovascular Diseases |
|
Arsenic |
3.54 | 15738583 17938729 19152805 |
MESH:D002340 |
Carotid Artery Diseases |
|
Arsenic |
4.43 | 18022660 16973168 |
MESH:D002471 |
Cell Transformation, Neoplastic |
|
sodium arsenite |
3.08 | 20056578 19524636 |
MESH:D018281 |
Cholangiocarcinoma |
|
Tetrachlorodibenzodioxin |
3.29 | 16835633 |
MESH:D002972 |
Cleft Palate |
|
Tetrachlorodibenzodioxin |
2.15 | 15668235 15340226 16354765 8697196 12621046 |
MESH:D003110 |
Colonic Neoplasms |
|
decitabine |
2.35 | 17616700 |
MESH:D015179 |
Colorectal Neoplasms |
|
decitabine |
2.10 | 18981723 |
MESH:D000013 |
Congenital Abnormalities |
|
Tetrachlorodibenzodioxin |
3.18 | 17141729 14669216 |
MESH:D019465 |
Craniofacial Abnormalities |
|
lead acetate |
2.97 | 19769572 |
MESH:D019465 |
Craniofacial Abnormalities |
|
Tetrachlorodibenzodioxin |
2.97 | 10048152 15322242 20055451 |
MESH:D003924 |
Diabetes Mellitus, Type 2 |
|
Tetrachlorodibenzodioxin |
1.69 | 17107852 |
MESH:D056486 |
Drug-Induced Liver Injury |
|
Tetrachlorodibenzodioxin |
1.57 | 20420201 |
MESH:D004362 |
Drug Toxicity |
|
Tetrachlorodibenzodioxin |
2.86 | 11462148 |
MESH:D004487 |
Edema |
|
Tetrachlorodibenzodioxin |
2.51 | 11000095 12711302 |
MESH:D004489 |
Edema, Cardiac |
|
Tetrachlorodibenzodioxin |
4.12 | 18230668 16714409 15322242 |
MESH:D004701 |
Endocrine Gland Neoplasms |
|
decitabine |
5.33 | 19294695 |
MESH:D004715 |
Endometriosis |
|
Mifepristone |
9.59 | 16134523 |
MESH:D004715 |
Endometriosis |
|
Tetrachlorodibenzodioxin |
9.59 | 10568697 9294722 |
MESH:D005124 |
Eye Abnormalities |
|
Tetrachlorodibenzodioxin |
3.12 | 11564622 |
MESH:D005313 |
Fetal Death |
|
Tetrachlorodibenzodioxin |
3.63 | 11858732 |
MESH:D005317 |
Fetal Growth Retardation |
|
lead acetate |
5.54 | 19769572 |
MESH:D005355 |
Fibrosis |
|
Tetrachlorodibenzodioxin |
3.12 | 20067830 |
MESH:D005534 |
Foot Diseases |
|
Arsenic |
5.78 | 6392382 |
MESH:D005833 |
Genital Neoplasms, Female |
|
sodium arsenite |
4.87 | 16452187 |
MESH:D006058 |
Gonadal Disorders |
|
Tetrachlorodibenzodioxin |
4.81 | 10696789 |
MESH:D006258 |
Head and Neck Neoplasms |
|
decitabine |
3.58 | 19215824 |
MESH:D006330 |
Heart Defects, Congenital |
|
Tetrachlorodibenzodioxin |
2.40 | 10048152 11294989 |
MESH:D006470 |
Hemorrhage |
|
Tetrachlorodibenzodioxin |
3.48 | 11000095 |
MESH:D006529 |
Hepatomegaly |
|
Tetrachlorodibenzodioxin |
3.07 | 15340226 12621046 16120746 |
MESH:D006561 |
Herpes Simplex |
|
Etoposide |
4.76 | 10809021 |
MESH:D006689 |
Hodgkin Disease |
|
Etoposide |
8.06 | 18180244 17606976 16135485 15147373 16200630 |
MESH:D006689 |
Hodgkin Disease |
|
sodium arsenite |
8.06 | 12676792 |
MESH:D006869 |
Hydronephrosis |
|
Tetrachlorodibenzodioxin |
4.26 | 18606429 15340226 16354765 8697196 16959395 |
MESH:D017488 |
Hyperkeratosis, Epidermolytic |
|
Arsenic |
4.59 | 17050553 |
MESH:D006973 |
Hypertension |
|
Arsenic |
5.39 | 16076760 9931084 11953799 |
MESH:D006973 |
Hypertension |
|
Tetrachlorodibenzodioxin |
5.39 | 18850075 18670907 |
MESH:D006987 |
Hypesthesia |
|
Arsenic |
5.78 | 16093927 |
MESH:D007248 |
Infertility, Male |
|
decitabine |
7.21 | 17581917 |
MESH:D007248 |
Infertility, Male |
|
sodium arsenite |
7.21 | 15346721 12646999 |
MESH:D007249 |
Inflammation |
|
Tetrachlorodibenzodioxin |
1.92 | 12200463 12878042 |
MESH:D007569 |
Jaw Abnormalities |
|
Tetrachlorodibenzodioxin |
3.48 | 16580747 |
MESH:D007642 |
Keratosis |
|
Arsenic |
5.18 | 16930632 12749816 |
MESH:D007674 |
Kidney Diseases |
|
Cadmium Chloride |
6.68 | 16962696 |
MESH:D007674 |
Kidney Diseases |
|
sodium arsenite |
6.68 | 20008137 |
MESH:D007938 |
Leukemia |
|
decitabine |
3.13 | 18980019 19235587 |
MESH:D007951 |
Leukemia, Myeloid |
|
decitabine |
4.14 | 17236224 18454857 19117987 |
MESH:D015470 |
Leukemia, Myeloid, Acute |
|
decitabine |
2.40 | 19387464 18206229 17679729 19010910 18704418 18460780 |
MESH:D015477 |
Leukemia, Myelomonocytic, Chronic |
|
decitabine |
5.68 | 18055864 |
MESH:D015473 |
Leukemia, Promyelocytic, Acute |
|
Arsenic |
3.64 | 17339181 |
MESH:D008106 |
Liver Cirrhosis, Experimental |
|
Tetrachlorodibenzodioxin |
1.24 | 12878042 |
MESH:D008107 |
Liver Diseases |
|
Arsenic |
2.57 | 11134558 |
MESH:D008113 |
Liver Neoplasms |
|
Arsenic |
7.75 | 16368122 |
MESH:D008113 |
Liver Neoplasms |
|
sodium arsenite |
7.75 | 16712894 15276417 |
MESH:D008113 |
Liver Neoplasms |
|
Tetrachlorodibenzodioxin |
7.75 | 16984957 |
MESH:D008114 |
Liver Neoplasms, Experimental |
|
Tetrachlorodibenzodioxin |
2.19 | 12151625 |
MESH:D008171 |
Lung Diseases |
|
sodium arsenite |
3.26 | 19095001 |
MESH:D008175 |
Lung Neoplasms |
|
Arsenic |
3.53 | 17306315 17976673 19168569 |
MESH:D008175 |
Lung Neoplasms |
|
sodium arsenite |
3.53 | 15276417 16712894 17077188 17306315 19931552 |
MESH:D008175 |
Lung Neoplasms |
|
Tetrachlorodibenzodioxin |
3.53 | 19555203 11884234 |
MESH:D008223 |
Lymphoma |
|
decitabine |
8.23 | 19470736 |
MESH:D008223 |
Lymphoma |
|
Etoposide |
8.23 | 12854902 12556972 |
MESH:D008545 |
Melanoma |
|
decitabine |
3.52 | 16505122 17785578 |
MESH:D008545 |
Melanoma |
|
sodium arsenite |
3.52 | 16487513 19082730 |
MESH:D009101 |
Multiple Myeloma |
|
decitabine |
3.44 | 18172295 |
MESH:D009190 |
Myelodysplastic Syndromes |
|
decitabine |
3.46 | 19157545 18608210 19010910 16882708 |
MESH:D017202 |
Myocardial Ischemia |
|
Arsenic |
9.38 | 15371236 |
MESH:D017202 |
Myocardial Ischemia |
|
Tetrachlorodibenzodioxin |
9.38 | 12213967 |
MESH:D009369 |
Neoplasms |
|
decitabine |
5.43 | 17925555 19116145 19470736 |
MESH:D009369 |
Neoplasms |
|
sodium arsenite |
5.43 | 11559025 |
MESH:D009374 |
Neoplasms, Experimental |
|
sodium arsenite |
3.84 | 20056578 |
MESH:D009421 |
Nervous System Malformations |
|
Tetrachlorodibenzodioxin |
3.37 | 14600291 |
MESH:D009436 |
Neural Tube Defects |
|
Arsenic |
7.75 | 16620997 |
MESH:D009436 |
Neural Tube Defects |
|
sodium arsenite |
7.75 | 12854658 |
MESH:D020078 |
Neurogenic Inflammation |
|
Arsenic |
4.52 | 17056641 |
MESH:D010051 |
Ovarian Neoplasms |
|
Arsenic |
11.70 | 17306315 |
MESH:D010051 |
Ovarian Neoplasms |
|
decitabine |
11.70 | 19259094 19331143 |
MESH:D010051 |
Ovarian Neoplasms |
|
Mifepristone |
11.70 | 16525653 |
MESH:D010051 |
Ovarian Neoplasms |
|
sodium arsenite |
11.70 | 15276417 17306315 |
MESH:D010190 |
Pancreatic Neoplasms |
|
decitabine |
5.82 | 19294695 |
MESH:D010190 |
Pancreatic Neoplasms |
|
Etoposide |
5.82 | 19003803 |
MESH:D010382 |
Peliosis Hepatis |
|
Tetrachlorodibenzodioxin |
4.47 | 12520081 |
MESH:D010523 |
Peripheral Nervous System Diseases |
|
Arsenic |
4.34 | 16093927 |
MESH:D016491 |
Peripheral Vascular Diseases |
|
Arsenic |
5.18 | 15371236 6392382 16905509 |
MESH:D017119 |
Porphyria Cutanea Tarda |
|
Tetrachlorodibenzodioxin |
3.72 | 18163543 |
MESH:D011297 |
Prenatal Exposure Delayed Effects |
|
Tetrachlorodibenzodioxin |
3.38 | 11896295 11399792 11118676 11222880 |
MESH:D055728 |
Primary Myelofibrosis |
|
decitabine |
4.90 | 17616702 |
MESH:D011471 |
Prostatic Neoplasms |
|
Arsenic |
2.71 | 16140617 |
MESH:D011471 |
Prostatic Neoplasms |
|
Etoposide |
2.71 | 17172428 |
MESH:D011471 |
Prostatic Neoplasms |
|
sodium arsenite |
2.71 | 16039940 |
MESH:D011507 |
Proteinuria |
|
Arsenic |
4.15 | 21343184 |
MESH:D015619 |
Respiratory System Abnormalities |
|
Tetrachlorodibenzodioxin |
4.00 | 18990726 |
MESH:D012208 |
Rhabdomyosarcoma |
|
decitabine |
4.55 | 19155313 |
MESH:D012512 |
Sarcoma, Ewing's |
|
Etoposide |
4.86 | 14601052 |
MESH:D012871 |
Skin Diseases |
|
Arsenic |
2.78 | 17548696 16353154 17050553 17938729 15952646 6392382 19834688 17453740 16702368 16759981 18709164 |
MESH:D012878 |
Skin Neoplasms |
|
Arsenic |
9.84 | 17029826 16251483 17976673 17050553 19538983 15504454 |
MESH:D012878 |
Skin Neoplasms |
|
sodium arsenite |
9.84 | 19524636 18572023 |
MESH:D012878 |
Skin Neoplasms |
|
Tetrachlorodibenzodioxin |
9.84 | 16192470 |
MESH:D016135 |
Spinal Dysraphism |
|
sodium arsenite |
3.90 | 12854658 |
MESH:D013274 |
Stomach Neoplasms |
|
decitabine |
2.10 | 19037991 |
MESH:D013959 |
Thyroid Diseases |
|
Tetrachlorodibenzodioxin |
4.12 | 12697716 |
MESH:D013964 |
Thyroid Neoplasms |
|
decitabine |
3.43 | 17967635 |
MESH:D001749 |
Urinary Bladder Neoplasms |
|
Arsenic |
8.73 | 11144890 15987713 19322015 18640142 17976673 17306315 19429237 |
MESH:D001749 |
Urinary Bladder Neoplasms |
|
decitabine |
8.73 | 19087683 17616700 |
MESH:D001749 |
Urinary Bladder Neoplasms |
|
sodium arsenite |
8.73 | 11723127 16712894 16452187 17306315 |
MESH:D002583 |
Uterine Cervical Neoplasms |
|
sodium arsenite |
3.90 | 11813266 |
MESH:D014604 |
Uveal Neoplasms |
|
decitabine |
5.13 | 17785578 |
MESH:D014652 |
Vascular Diseases |
|
Arsenic |
12.51 | 17056641 |
MESH:D014652 |
Vascular Diseases |
|
sodium arsenite |
12.51 | 17056641 |
MESH:D054079 |
Vascular Malformations |
|
Tetrachlorodibenzodioxin |
4.81 | 12125929 |
MESH:D019282 |
Wasting Syndrome |
|
Tetrachlorodibenzodioxin |
4.47 | 15886252 |